Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
| 2.39 | |
| 2.43 | |
| - | |
| 2.44 | |
| 2.32 | |
| 0.92-3.73 | |
| 842 M | |
| 361 M | |
| 2 310 K | |
| -0.2 | |
| 1.358 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Over the long run, Wall Street has proved to be a surefire wealth creator. But over shorter periods, the performance of the major stock indexes is unpredictable. Since this decade began, the Dow Jones...
Although it's been an adventurous couple of years for investors, 2023 turned out to be a phenomenal year for the bulls. The Dow Jones Industrial Average climbed to a fresh all-time high, while the S&P...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
